
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 17, 2026, 6:58 AM ET
Morgan Stanley lifts Moderna price target to $200, maintains Equal-Weight rating
Nasdaq: $MRNABiotechnology · mRNA medicinesPositive Phase 3 in melanoma$3.0 billion of 0% converts due 2032Norovirus interim missed its bar
MRNA Stock Hub: Moderna News, mNEXSPIKE and the Cancer Vaccine
Moderna reported $1,313 million of revenue in the September 2026 quarter, up 29%, and net income of $162 million, or $0.38 a share, a return to profit after three years of annual losses. It raised revenue growth guidance to 15%–25% from up to 10% and lifted expected year-end cash to $8.1–8.3 billion after issuing $3.0 billion of zero-coupon convertible notes. The re-rating rests on one result: in the Phase 3 INTerpath-001 trial, intismeran autogene plus KEYTRUDA cut the risk of recurrence or death by 42% in resected melanoma.
Full research report · PDF
Moderna (MRNA) research report, as of November 19, 2026
17 pages: the September quarter and the nine-month cash flow, the COVID franchise and the 2026–2027 strain update, mFLUSIVA and the combination vaccine, intismeran autogene and the INTerpath program, the $3.0 billion convertible notes and the amended Ares credit agreement, the Arbutus settlement and the remaining patent litigation, dilution and ownership, sources and FAQ. Available in the Merlintrader Research Library. The report is a dated snapshot and is not updated after that date; this page follows the current situation. For personal use only: redistribution prohibited.
Next catalyst
December 12, 2026 · ASH oral presentation for mRNA-2808 · propionic acidemia pivotal data expected by December 31, 2026
Moderna said on November 6, 2026 that an abstract on mRNA-2808, its T-cell engager program in multiple myeloma, was accepted for oral presentation at the American Society of Hematology meeting on December 12 in New Orleans. The same release says the registrational study of mRNA-3927 in propionic acidemia has reached target enrollment, with pivotal data expected in 2026. The acidemia readout has no published date inside that window. Third-quarter release, November 6, 2026
Completed: on November 9, 2026 Moderna amended its credit agreement with Ares Capital Corporation, cutting the margin by 0.75 percentage points to Term SOFR plus 4.75% and extending the term loan maturity to November 24, 2031 (Form 8-K). On November 13, 2026 Chief Legal Officer Shannon Thyme Klinger signed a retirement agreement under which she remains an employee until March 31, 2027 and transitions her duties (Form 8-K).
MRNA stock at a glance
Chart analysis · JC
Technical chart analysis of $MRNA with bull and bear scenarios on JC Just Charts.
Cash + investments · Sep 30
$7,976M
$1,195M cash, $3,976M current and $2,805M non-current investments; $8,135M at December 31, 2025.
Revenue · September quarter
$1,313M
Product sales $1,273M plus $40M of other revenue; $1,847M in nine months.
Net income · September quarter
$162M
Diluted earnings of $0.38 on 430 million diluted shares; the nine-month net loss was $1,963M, or $4.93 a share.
Operating cash use · nine months
$2,715M
The September quarter alone used $1,559M, including the $950 million Arbutus and Genevant settlement paid in July.
Debt · Sep 30
$3,549M
$2,958M carrying amount of the 2032 convertible notes plus $591M carrying amount of the Ares term loan.
Short interest · Oct 30
8.2%
33,191,285 shares against 404,620,975 shares outstanding at October 30, 2026; 1.8 days to cover.
Where Moderna stands now
Moderna is a commercial biotechnology company with five approved vaccines and its first positive Phase 3 oncology result. In the quarter ended September 30, 2026 revenue was $1,313 million against $1,016 million, net income $162 million against a loss of $200 million, and income from operations $130 million, the first positive operating line in three years. The nine-month net loss was $1,963 million, because the first quarter absorbed an $876 million cost-of-sales charge for the Arbutus and Genevant settlement, on a much smaller product base. Form 10-Q, September 30, 2026 · Results release
The clinical news matters more. In August 2026 Moderna and Merck reported that INTerpath-001, the Phase 3 trial of intismeran autogene plus KEYTRUDA in completely resected stage IIB–IV melanoma, met its primary endpoint of recurrence-free survival at a pre-specified interim analysis; at the European Society for Medical Oncology (ESMO) meeting in October, after 24.6 months of median follow-up, the combination had cut the risk of recurrence or death by 42% (hazard ratio 0.58; p<0.001) and the risk of distant metastasis or death by 38% (0.62; p=0.002). Form 10-Q, business highlights
Two programs moved the other way. The norovirus Phase 3 interim missed the statistical criteria for early success and Moderna no longer plans an additional cohort this season, and the flu plus COVID combination vaccine still has no U.S. filing date. Third-quarter release
The main risk: the balance sheet changed shape in September. Moderna issued $3.0 billion of zero-coupon convertible notes due 2032 at an initial conversion price of about $210.58 a share, spent $329 million on capped calls and ended September with $7,976 million of cash and investments against $3,549 million of debt. The converts carry no coupon, but they are senior unsecured obligations convertible into about 14 million shares, or up to 21 million in limited circumstances, and interest expense has already moved from $2 million in the first nine months of 2025 to $52 million. One profitable quarter does not service $3.6 billion of principal.
▲ The constructive case
Five approved products, a positive Phase 3 in melanoma with a 42% reduction in the risk of recurrence or death, nine Phase 2 and Phase 3 trials for intismeran, $7,976 million of liquid assets against $3,549 million of debt, and full-year revenue guidance raised to 15%–25% from up to 10%. Research spending is falling, cost of sales excluding the settlement rose 14% on 47% higher product sales, and the term loan was repriced 0.75 points lower with a one-year extension. If intismeran is filed and approved, Moderna stops being a respiratory company with an oncology option.
▼ The cautious case
Ninety-eight percent of product sales in the quarter came from COVID vaccines, and the full-year guidance implies a fourth quarter below the $678 million reported a year earlier. The norovirus interim failed, the combination vaccine has no U.S. filing and awaits FDA guidance on refiling, and the influenza launch arrived after contracting closed. The quarter came with a $1,559 million operating cash outflow including a $950 million legal payment, $1,367 million of accounts receivable and $1,324 million of gross-to-net deductions. Convertible notes, 27.2 million options, 11.2 million unvested units and up to $1.3 billion of additional Arbutus exposure sit on 404.6 million shares.
Latest Moderna news
Nov 17, 2026
Morgan Stanley lifts Moderna price target to $200, maintains Equal-Weight rating
Morgan Stanley raised its price target on Moderna to $200 from $95. The bank kept its Equal-Weight rating on the stock. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Nov 16, 2026
Moderna amends Credit and Guaranty Agreement, lowering interest margins and extending maturity
On November 9, 2026, Moderna entered into Amendment No. 1 to its Credit and Guaranty Agreement dated November 19, 2025, with Ares Capital Corporation as administrative agent and collateral agent. The amendment reduces interest rate margins on initial and delayed draw term loans by 0.75 percentage points, from 5.50% to 4.75% for term rate loans and from 4.50% to 3.75% for base rate loans. The maturity date moves from November 24, 2030 to November 24, 2031, and the delayed draw availability period is extended to November 24, 2029.
Nov 13, 2026
Moderna's Chief Legal Officer Shannon Thyme Klinger to retire March 31, 2027
Moderna entered into a Transitional Services and Retirement Agreement with Chief Legal Officer Shannon Thyme Klinger, who will continue employment until March 31, 2027. Until then she will keep her current base salary, benefits and equity vesting, and is eligible for a 2026 bonus based on her target bonus. Severance totals $1,628,300, paid over twelve months, with COBRA premiums covered until September 30, 2028. She may also receive $2,500,000 if Moderna prevails in litigation with Arbutus and Genevant, and up to $5,500,000 tied to the Pfizer and BioNTech litigation.
Nov 12, 2026
Moderna outlines next phase of growth at analyst day
Moderna outlined its mid-term financial strategy and growth priorities at its 2026 Analyst Day, highlighting intismeran following positive Phase 3 results in adjuvant melanoma. In the Phase 3 INTerpath-001 study, intismeran in combination with KEYTRUDA showed a 42% reduction in the risk of recurrence or death compared with KEYTRUDA alone. The Marlborough, Massachusetts facility is expected to become the global supply site for intismeran in 2027. The limited U.S. launch of mFLUSIVA has delivered more than 110,000 vaccinations.
Nov 11, 2026
Moderna announces JAMA Network Open publication of mNEXSPIKE comparative effectiveness data
A real-world study of 294,499 matched U.S. Veterans aged 65 and older, published in JAMA Network Open, found mNEXSPIKE had 35.9% relative vaccine effectiveness against medically attended COVID-19 compared with Comirnaty (95% CI: 20.4%-49.7%). Relative vaccine effectiveness against COVID-19-associated hospitalization was 47.0% (95% CI: 5.4%-74.8%). An exploratory analysis showed 39.3% relative vaccine effectiveness for MACE hospitalization (95% CI: 11.8%-57.0%). Moderna supported the observational study.
Nov 11, 2026
Moderna CEO says intismeran could eventually outsell Keytruda, citing plans to test it in Keytruda's indications
Moderna CEO Stéphane Bancel said at a Financial Times summit on 10 November that intismeran autogene could over time be bigger than Keytruda, as the company plans to test it everywhere Keytruda works. In October Phase III results (NCT05933577), intismeran plus Keytruda cut the risk of melanoma death or recurrence by 42%. Intismeran is also in trials for NSCLC, bladder cancer and pancreatic cancer, and Moderna reported Q3 revenue of $1.3bn, up 29%. Not confirmed by a company release or filing at the time of writing; to be verified.
Moderna stock catalysts: the dated calendar
- August 2026 — INTerpath-001 topline: recurrence-free and distant metastasis-free survival met at a pre-specified interim analysis. Completed · company statement in the Form 10-Q
- September 1, 2026 — $3.0 billion of 0.00% convertible notes due 2032 issued, including the full $400 million option. Completed · Form 10-Q, Note 11
- November 6, 2026 — Third-quarter results: revenue of $1,313 million, net income of $162 million, full-year revenue growth guidance raised to 15%–25%. Completed · results release
- November 9, 2026 — Amendment No. 1 to the Ares credit agreement: margin down 0.75 points, maturity to November 2031. Completed · Form 8-K
- November 13, 2026 — Retirement agreement for Chief Legal Officer Shannon Thyme Klinger, who stays until March 31, 2027. Completed · Form 8-K
- December 12, 2026 — Oral presentation on mRNA-2808 at the American Society of Hematology meeting in New Orleans. Company-announced
- By December 31, 2026 — Pivotal data from the registrational study of mRNA-3927 in propionic acidemia. Company expectation
The five products and the pipeline
COVID · COMMERCIAL
Spikevax and mNEXSPIKE
$1,244 million of the $1,273 million of product sales in the September quarter. mNEXSPIKE was about 24% of U.S. retail COVID vaccinations in 2025 and nearly a third among adults 65 and older; the 2026–2027 formulas carry the JN.1-lineage XFG subvariant.
INFLUENZA · APPROVED
mFLUSIVA (mRNA-1010)
Approved by the FDA in August 2026 for adults 50 and older, with accelerated approval for 65 and older that requires a confirmatory trial. Approved in Canada, under review in the EU, Australia and Taiwan. Launched in September 2026 into a closed contracting cycle, with sales immaterial in the quarter.
RSV · APPROVED
mRESVIA (mRNA-1345)
$29 million of sales in the quarter and $39 million in nine months. Approved in the EU for adults 60 and older and for high-risk adults aged 18 to 59, and covered by a joint procurement contract with the European Commission on behalf of six countries for up to 24 million doses.
FLU + COVID · APPROVED ABROAD
mCOMBRIAX / mCOFLU (mRNA-1083)
Approved in the European Union in April 2026 and in Canada, not commercialized at September 30, under review in Japan, the United Kingdom and Australia, with no U.S. filing.
ONCOLOGY · PHASE 3
Intismeran autogene (mRNA-4157)
Individualized neoantigen therapy developed with Merck on an equal cost and profit share. Nine Phase 2 and Phase 3 trials, including three Phase 3 studies in non-small cell lung cancer and INTerpath-001 in adjuvant melanoma.
RARE DISEASE · REGISTRATIONAL
mRNA-3927 and mRNA-3705
Propionic acidemia: registrational study at target enrollment, pivotal data expected in 2026, partnered with Recordati after a $50 million upfront payment. Methylmalonic acidemia: the pivotal study decision is deferred until that readout.
Moderna deep dive: the full analysis
The chapters below work through the business with the numbers of the September 2026 quarter: the scenarios, what would falsify them, the platform, the dated catalysts, the quality of the revenue, the COVID franchise, influenza and RSV, the melanoma result, the new debt, dilution and ownership, the government contracts and the litigation, and the main risks. The same research is available as a PDF in the Research Library. The Merlintrader Research Library collects our dated biotechnology stock research reports.
01 Three scenarios: one profitable quarter, a levered balance sheet and a pipeline that has to carry 2027
Bull case — intismeran becomes a second franchise
The favorable path starts with the result Moderna already has. INTerpath-001 randomized patients with completely resected stage IIB–IV melanoma and, at a pre-specified interim analysis, showed a 42% reduction in the risk of recurrence or death for intismeran plus KEYTRUDA against KEYTRUDA alone, with a 38% reduction in the risk of distant metastasis or death. That is efficacy in the adjuvant setting, where the comparator is the standard of care and the endpoint is the one regulators accept. Moderna and Merck are working toward submissions, and the same individualized manufacturing model applies to the lung cancer trials behind it. Form 10-Q, business highlights
The second leg is commercial breadth. The combination and influenza vaccines change the shape of the respiratory business, because one visit can carry two indications and influenza is a larger, more stable market than COVID. In the bull case mFLUSIVA converts the 2027–2028 contracting season, mCOMBRIAX finds a U.S. filing path, and the partnerships with the United Kingdom, Canada, Australia, Mexico, Brazil and the European Commission become contracted revenue. The financial leg is visible: $7,976 million of cash and investments, $900 million of undrawn delayed draws and no coupon on the converts. Third-quarter release
Base case — a good respiratory year and an oncology filing in 2027
In the middle case the third quarter was what it looks like: a seasonal peak loaded with European government deliveries, a profit at the operating line, and a fourth quarter that gives much of it back. Full-year revenue lands inside the $2.24–2.43 billion implied by 15%–25% growth over 2025 revenue of $1,944 million (Merlintrader calculation) and the net loss for the year is roughly $2.8–3.0 billion on the expense framework in the third-quarter release (Merlintrader calculation). Intismeran is filed during 2027 and reviewed through 2027 and 2028, with the lung cancer readouts later and a real chance that one disappoints; the propionic acidemia readout expected by December 31, 2026 would test whether the platform works as a therapeutic and not only as a vaccine. Third-quarter release
Bear case — the fourth quarter disappoints and the patent tail costs more
The adverse path has three parts. Demand first: COVID is still 98% of product sales, the U.S. market is contracting, and the guidance implies a fourth quarter of $389–583 million against $678 million a year earlier. Pipeline second: two programs have already failed or stalled in 2026, and a third failure would leave melanoma as the only near-term value driver. Legal third: Moderna has appealed the Arbutus and Genevant decision on 28 U.S.C. § 1498 and could owe up to $1.3 billion more, the European Patent Office revoked European Patent No. 3 590 949 in September 2026, and CureVac has opened cases in three jurisdictions. Form 10-Q, Note 12 and Part II, Item 1
Dilution closes the circle: the converts add about 14 million shares, the capped calls offset that only up to a cap of about $392.62, and 38 million shares were already reserved for awards.
02 What would falsify this reading
The reading here is that Moderna has moved from a declining COVID company to a funded company with a credible oncology asset, while still losing money across a full year. These developments would change it.
- A fourth quarter far below the implied range. Growth of 15%–25% over $1,944 million implies fourth-quarter revenue of $389–583 million (Merlintrader calculation). A print below $389 million, or a cut to the range before that report, would show that the September quarter was a delivery-timing event rather than a demand recovery. Source
- An intismeran filing that slips. The Phase 3 result is strong, but the filing has no date. A delay past 2027, a request for mature overall survival or a validation problem in individualized manufacturing would leave the valuation resting on respiratory revenue. Source
- Gross-to-net rising faster than gross sales. In the September quarter gross product sales of $2,597 million carried $1,324 million of deductions, or 51%. A further rise without matching volume would mean the growth is being bought through concessions. Form 10-Q, Note 3
- An adverse outcome on the Arbutus appeal. Up to $1.3 billion would be about a sixth of the September cash and investments, arriving as a single cash event rather than as a charge inside a profitable year. Form 10-Q, Note 12
- Another late-stage failure. Propionic acidemia is the nearest test: a miss would remove the rare disease leg, weaken the case for mRNA as a therapeutic platform and load more weight on lung cancer. Source
- A binding liquidity covenant. The credit agreement requires minimum cash of $500 million, rising to $750 million if more than $1.0 billion is drawn, tested weekly unless the trailing 30-day average market capitalization, measured over that window, is above the threshold of $5.0 billion. A decline that removes the exemption, with a larger draw, would make it bind. Form 10-Q, Note 11
03 What Moderna does: mRNA, lipid nanoparticles and five approved products
Moderna makes medicines out of messenger RNA. The molecule instructs a patient’s cells to produce a protein — an antigen in a vaccine, an enzyme in a rare disease therapy, a set of tumor-specific neoantigens in oncology — and the body does the manufacturing. Everything else follows from two problems: getting the RNA into the cell intact, and making it at scale to a specification regulators accept. Form 10-Q, Note 1
Delivery is the lipid nanoparticle: a four-component formulation of an ionizable lipid, a helper lipid, cholesterol and a PEGylated lipid that encapsulates the mRNA and releases it in the cytosol after endosomal uptake. The ionizable lipid does the work, remaining neutral at physiological pH and becoming protonated in the acidifying endosome, which disrupts the membrane and lets the payload escape. Moderna’s SM-102 was selected from about thirty candidates on biodegradability, tolerability, expression and immunogenicity, with an apparent pKa around 6.7. Hald Albertsen et al., Advanced Drug Delivery Reviews 2022
That chemistry explains why the platform travels and why the side effects travel with it. The same particle can carry a spike antigen, a prefusion F protein, a hemagglutinin or a neoantigen string, and the manufacturing steps carry over with the sequence. The reactogenicity that runs through the class — mostly mild to moderate reactions, with a shared inflammatory signature that peaks the day after vaccination — is partly a property of the delivery system. Fierro et al., Frontiers in Immunology 2025
Manufacturing is the third leg. Moderna runs Cambridge and Norwood in Massachusetts, a Marlborough plant built for intismeran that began supplying clinical batches in September 2025, and sites in the United Kingdom, Canada and Australia. It had about 4,700 employees in 18 countries at December 31, 2025, after lowering annual operating expenses by approximately $2.2 billion. Revenue fell from $6,848 million in 2023 to $3,236 million in 2024 and $1,944 million in 2025; nine months of 2026 produced $1,847 million. Form 10-K for 2025 Fourth-quarter 2025 release
04 Moderna stock catalysts: the dated calendar to the end of 2026
Two events carry the next six weeks, and only one has a date. The ASH oral presentation on mRNA-2808 falls on December 12, 2026 in New Orleans. mRNA-2808 is a T-cell engager built on the mRNA platform, aimed at multiple myeloma, and the abstract was accepted for oral presentation, an acceptance that puts the program in an oral session. An oral presentation at a major hematology meeting is a disclosure event, not an approval event: the market will read response rates in an early-phase setting, and the program is years from a filing. Third-quarter release
The second is the propionic acidemia readout. The registrational study of mRNA-3927 reached target enrollment and Moderna expects pivotal data in 2026. The program is partnered with Recordati, which paid $50 million upfront, with the transaction closing on March 16, 2026, holds an exclusive worldwide license to develop and commercialize the product, and owes up to $110 million of development and regulatory milestones plus tiered royalties, while Moderna leads clinical development through approval. The commercial value is small; the information value is not, because this is the cleanest test of whether an mRNA therapeutic given repeatedly can change the course of a metabolic disease. Form 10-Q, Note 5
Behind those, the calendar is a set of intentions. Regulatory submissions for intismeran would ordinarily follow a discussion of the Phase 3 package with the FDA, and nothing in the filings commits to a month. The agency’s guidance on refiling mCOMBRIAX is awaited and the wording has not changed since February. The fourth-quarter and full-year 2026 results are the next scheduled financial disclosure, and Moderna has not announced the date. Form 10-Q, business highlights
05 The September quarter: $1.3 billion of revenue and a positive operating line
Total revenue was $1,313 million, of which net product sales were $1,273 million and other revenue $40 million: product sales grew 31% and total revenue 29%. Cost of sales was $318 million, up 54%, and included $65 million of third-party royalties, $54 million of inventory write-downs and $29 million of unutilized capacity costs, taking the ratio to net product sales and stand-ready revenue to 24% from 21%. Research fell 27% to $583 million on $127 million less clinical trial spending, and selling and administrative expense rose 5% to $282 million on higher legal costs. Form 10-Q, MD&A
Income from operations was $130 million against a loss of $260 million a year earlier. Below the line, interest income fell 15% to $62 million and other expense was $21 million, driven by $18 million of interest that did not exist a year earlier because the term loan was drawn in November 2025 and the converts were issued in September 2026. Pre-tax income was $171 million and the tax provision $9 million, for net income of $162 million. Diluted earnings were $0.38 on 430 million shares against $0.40 basic on 401 million, with the notes adding about 5 million shares and equity awards 24 million. Form 10-Q, Note 15
The nine-month picture is what the full year will look like. Cost of sales was $1,366 million against $416 million, of which $890 million came from the Arbutus and Genevant settlement and its intangible amortization; excluding those, cost of sales rose 14% while the ratio to net product sales fell eight percentage points. Research fell 20% to $1,883 million and selling and administrative expense 5% to $671 million, leaving an operating loss of $2,073 million. With $201 million of interest income, $58 million of other expense and a $33 million tax provision, the net loss was $1,963 million, or $4.93 a share. Form 10-Q, statements of operations
Two details recur. Stock-based compensation was $127 million in the quarter and $351 million in nine months, which is dilution even when it is not cash. And the tax rate says nothing about profitability: a full valuation allowance against most deferred tax assets produced an effective rate of 5.3% in the quarter and −1.7% in the nine months. Form 10-Q, Note 14
06 Revenue quality: Europe, the gross-to-net gap and the implied fourth quarter
The geographic split was $771 million in the United States and $314 million in Europe, against $782 million and $16 million a year earlier. The European line is not a new market: it is the timing of deliveries under long-term partnerships with governments. In nine months Europe contributed $569 million against $16 million and the United States $914 million against $901 million, so the growth of 2026 has come from outside the United States, from contracts that are lumpy by construction. Form 10-Q, Note 3
Gross-to-net is the second thing to read. Gross product sales of $2,597 million carried $1,070 million of chargebacks, discounts and fees and $254 million of returns, rebates and other fees, leaving $1,273 million net: a 51% deduction, the same ratio as a year earlier on $1,971 million of gross sales. The absolute numbers are large because the U.S. book runs through wholesalers with chargebacks to government programs, where the accrued liability for returns and other fees was $600 million at September 30, in addition to $1,235 million of chargebacks, discounts and fees netted against receivables. The stable ratio is the reassuring part; the size of the gross figure is why a headline growth rate can look better than the cash that follows it. Form 10-Q, Note 3
Cash conversion lagged the income statement. Accounts receivable rose to $1,367 million net from $184 million at December 31, 2025, because most third-quarter sales were uncollected at quarter-end; inventory rose to $313 million from $153 million for the respiratory season. Those lines explain why a quarter with $162 million of net income still consumed $1,559 million of operating cash, of which $950 million was the settlement payment. Form 10-Q, balance sheet and cash flow
Then the arithmetic for the next print. Growth of 15%–25% over 2025 revenue of $1,944 million gives $2,236–2,430 million; subtracting the $1,847 million already reported leaves fourth-quarter revenue of $389–583 million (Merlintrader calculation). Against $678 million a year earlier, the range implies a decline of 14% to 43% immediately after a quarter that grew 29%: either the third quarter pulled European deliveries forward, or the range keeps headroom after a fifteen-point raise. The fourth-quarter print decides between the two readings. Third-quarter release Fourth-quarter 2025 release
07 The COVID franchise: mNEXSPIKE, the strain update and waning protection
COVID vaccines produced $1,244 million of the $1,273 million of product sales in the September quarter; the company has five approved products, and one disease is paying for them. Inside the category the mix has shifted toward mNEXSPIKE, approved in 2025 for adults 65 and older and high-risk adults 12 to 64, which Moderna said was about 24% of U.S. retail COVID vaccinations in 2025 and nearly a third among adults 65 and older. Shareholder letter, January 5, 2026
The product cycle is annual and strain-driven. In August 2026 the FDA approved the 2026–2027 formulas of Spikevax and mNEXSPIKE carrying the JN.1-lineage XFG subvariant: the vaccine follows the virus and revenue depends on how many people accept an annual dose. Policy has moved against volume, since the FDA revoked the emergency use authorization in August 2025, leaving the licensed products in place but closing the emergency channel. Form 10-Q, business highlights Form 10-K, government regulation
The literature explains why the market settled where it did. In a living systematic review and meta-analysis of 68 studies, Wu et al. found that effectiveness against infection with any strain fell from 83% at 14–42 days after the primary series to 62% at 112–139 days, while effectiveness against hospitalization fell from 92% to 79% over about eight months. Boosters restored protection to 70% against infection and 89% against hospitalization, then decayed again. That pattern is why an annual revaccination market exists rather than a durable one. Wu et al., The Lancet Respiratory Medicine 2023
The variant dimension is sharper. In a Danish nationwide cohort, two doses gave 39.9% protection against Omicron infection at 14–30 days in adults 60 and older and 4.4% after 120 days, while protection against hospitalization was 95.5% or higher. In Qatar, BNT162b2 effectiveness against symptomatic BA.1 infection peaked at 46.6% in the first three months after the second dose and fell to about 10%, rebounding to 59.9% after a booster, with 70%–80% protection against hospitalization after two doses. A 2026 review of 30 observational studies across the Omicron spectrum finds the same: modest protection against infection, substantial but declining protection against severe outcomes, weakest in the oldest groups. Gram et al., PLOS Medicine 2022 Chemaitelly et al., Nature Communications 2022 Alhumaid et al., BMC Infectious Diseases 2026
08 Influenza and RSV: three products at different stages
mFLUSIVA had the strangest approval path of the five. In February 2026 the FDA’s Center for Biologics Evaluation and Research refused to file the application, citing as the sole reason the choice of a licensed standard-dose influenza comparator, which it said did not reflect the best available standard of care. Moderna noted that neither the regulation nor the agency’s guidance for seasonal influenza vaccines contains such a requirement, and that CBER had agreed in writing in April 2024 to that comparator with a recommendation to add a high-dose arm for participants over 65. It requested a Type A meeting. Company release, February 10, 2026
Six months later the application was approved. The FDA cleared mFLUSIVA in August 2026 for adults 50 and older, with the approval for ages 50 through 64 resting on a randomized, observer-blind, active-controlled Phase 3 trial of 40,805 adults in 11 countries, and gave accelerated approval for adults 65 and older on immunogenicity in a 2,992-patient U.S. trial plus a descriptive relative efficacy analysis. Approval came after the 2026–2027 contracting cycle closed, so the launch is limited. Moderna also has approval in Canada and reviews in Europe, Australia and Taiwan. Form 10-Q, business highlights
RSV is further along and smaller than expected: mRESVIA generated $29 million in the quarter and $39 million in nine months, against $2 million and $4 million a year earlier. Efficacy is not the constraint. In the pivotal Phase 2–3 trial of 35,541 adults aged 60 and older, Wilson et al. reported vaccine efficacy of 83.7% against RSV lower respiratory tract disease with at least two signs or symptoms and 68.4% against RSV acute respiratory disease, with solicited local reactions in 58.7% of recipients against 16.2% on placebo. The constraint is a market shared with two protein vaccines that arrived first. Wilson et al., New England Journal of Medicine 2023
The competitive benchmark is documented. The adjuvanted RSVPreF3 OA vaccine showed 82.6% efficacy against RSV lower respiratory tract disease over one season in 24,966 adults aged 60 and older, 67.2% over two seasons and 62.9% over three, with revaccination adding no benefit; the bivalent RSVpreF vaccine showed 66.7% against illness with at least two signs and 85.7% with at least three. Three products with comparable efficacy, differentiated by tolerability, price and contract access. Moderna’s answer in Europe was a joint procurement contract with the European Commission for up to 24 million doses. Papi et al., NEJM 2023 Ison et al., The Lancet Respiratory Medicine 2025 Walsh et al., NEJM 2023
The combination vaccine has the clearest commercial logic and the least regulatory clarity. mCOMBRIAX was approved by the European Commission in April 2026 for adults 50 and older and in Canada as mCOFLU, and is under review in Japan, the United Kingdom and Australia, but has no U.S. filing: Moderna awaits FDA guidance on refiling. Until that changes, the U.S. franchise remains two separate shots. Form 10-Q, Note 1
09 Intismeran autogene: the melanoma result and what it is worth
Intismeran autogene is an individualized neoantigen therapy: Moderna sequences a patient’s tumor, identifies the mutations likely to produce immunogenic peptides, encodes a set of neoantigens in one mRNA molecule and manufactures a patient-specific dose given with Merck’s KEYTRUDA. It is the hardest product in the portfolio to make and the one with the largest payoff, because it is a template for any tumor with enough mutations. The companies share costs and profits equally, Merck leads clinical trials and Moderna leads process development and manufacturing. Form 10-Q, Note 5
The Phase 2b evidence came first. In KEYNOTE-942, 157 patients with completely resected stage IIIB–IV melanoma were randomized 2:1 to mRNA-4157 plus pembrolizumab or pembrolizumab alone; Weber et al. reported a hazard ratio for recurrence or death of 0.561 (95% confidence interval 0.309–1.017; p=0.053), 18-month recurrence-free survival of 79% against 62%, and no mRNA-4157-related grade 4 or 5 events. The three-year update held the hazard ratio at 0.510 for recurrence-free and 0.384 for distant metastasis-free survival; at five years recurrence-free survival was 68.8% against 49.1%, with an overall survival trend at 0.471 (0.165–1.345). Weber et al., The Lancet 2024 Carlino et al., JCO Oncology Advances 2026 Khattak et al., Journal of Clinical Oncology 2026
The Phase 3 result is what changed the valuation. INTerpath-001 enrolled patients with completely resected stage IIB–IV melanoma and met its primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival at a pre-specified interim analysis. At ESMO, after a median follow-up of 24.6 months, the combination reduced the risk of recurrence or death by 42% (hazard ratio 0.58, 0.45–0.75; p<0.001) and the risk of distant metastasis or death by 38% (0.62, 0.45–0.85; p=0.002), consistently across subgroups. Overall survival is immature with a favorable trend. Form 10-Q, business highlights
The piecewise analysis is the most informative part of the disclosure. In the first six months, while patients received the immunization regimen, the combination was comparable to KEYTRUDA alone for recurrence or death (hazard ratio 0.99, 0.66–1.49) and for distant metastasis (1.01, 0.58–1.79). After six months, in a pre-specified sensitivity analysis, it reduced the risk of recurrence or death by 58% (0.42, 0.30–0.58) and halved the risk of distant metastasis or death (0.50, 0.34–0.73). The benefit appears after the course is complete, which makes nine doses over about six months the operational problem: the patient has had surgery and feels well.
What it is worth depends on two unknowns. The label will define the population, since the addressable size depends on stage restrictions and on the risk-benefit against existing adjuvant programmed cell death protein 1 (PD-1) therapy. Execution is the second: a personalized product needs sequencing, epitope selection and a dedicated manufacturing slot per patient within a turnaround that keeps the dose relevant, which is why Moderna built Marlborough. Melanoma is the first read; the three Phase 3 lung cancer studies decide how large the franchise becomes. Form 10-Q, business highlights First-quarter release
10 Cash, the $3.0 billion convertible notes and the amended credit agreement
Cash and investments were $7,976 million at September 30, 2026: $1,195 million of cash, $3,976 million of current and $2,805 million of non-current investments in Treasury bills and notes, corporate debt and certificates of deposit. The total was $8,135 million at December 31, 2025, so it fell by only $159 million in nine months despite $2,715 million of operating cash use, because the convertible issue added $2,600 million net of the capped calls. Form 10-Q, Note 6 and MD&A
The quarterly cash flow is the way to read the burn. Operations used $630 million in the first quarter, $526 million in the second and $1,559 million in the third (Merlintrader calculation); the third included the $950 million settlement, so underlying use was about $609 million. Capital expenditure was $146 million in nine months. On that pattern a normal quarter consumes $500–650 million, and the year-end guide implies a fourth quarter that adds to the balance. Form 10-Q, cash flow statement
The convertible notes are the main change in the capital structure. On September 1, 2026 Moderna issued $3.0 billion of 0.00% convertible senior notes due March 1, 2032, including the full $400 million option, for net proceeds of about $3.0 billion before the $329 million of capped calls. The initial conversion rate is 4.7487 shares per $1,000 of principal, a conversion price of about $210.58 and a 47.5% premium, convertible into about 14 million shares and up to about 21 million in limited circumstances. Holders may convert before December 1, 2031 only if a share-price condition, a trading-price condition, a redemption or a corporate event is met, and none was met at September 30. Moderna may redeem from September 6, 2029 if the shares trade at 130% of the conversion price. Form 10-Q, Note 11
The capped calls are a hedge, not a repayment: $329 million for options on about 14 million shares with a strike at the conversion price and a cap near $392.62, recorded as a reduction of additional paid-in capital. Inside the cap they offset dilution; above it, dilution resumes. The term loan is the other half: $600 million drawn of a $1.5 billion facility led by Ares Capital, secured by substantially all assets, with $900 million of delayed draws. Amendment No. 1 of November 9, 2026 cut the margin 0.75 points to Term SOFR plus 4.75% and extended the maturity to November 2031. The rate on the initial loan was about 9.23% at September 30. Form 10-Q, Note 11 Form 8-K, November 16, 2026
None of this raises a continuity question: the company states that its cash and investments, with expected product sales and available borrowings, fund operations and capital expenditure for at least twelve months from the issuance of the financial statements. The balance sheet is an allocation question, not a survival question: the business spends about $3.4 billion a year on research and administration and needs a 2027 launch to change the slope. Form 10-Q, operation and funding requirements
11 Dilution, ownership and short interest
Shares outstanding were 404,620,975 at October 30, 2026, against 404 million at September 30 and 394 million at December 31, 2025. The increase came from option exercises and vesting, not an offering: the nine-month financing cash flow shows $172 million of proceeds from equity plans and no at-the-market sales. The $3.0 billion raised in September was debt. Form 10-Q, cover page and cash flow
The overhang is large but structured. At December 31, 2025 there were 27.18 million options outstanding at a weighted average exercise price of $38.63 and 11.20 million unvested units; 62 million shares were reserved under the equity plans, of which 38 million were subject to awards already granted. Add the 14 million shares underlying the converts, offset within the cap by the capped calls, and the fully diluted count is well above the basic one. On the other side, the board’s $3.0 billion repurchase authorization still has $1.7 billion outstanding, unused in 2025 and in the first nine months of 2026. Form 10-K, Note 13 Form 10-Q, Note 13
Ownership is concentrated in index and active managers. FMR LLC reported 58,929,948 shares, 14.8% of the class, at September 30, 2026, up from 51,803,891 shares and 13.1% at June 30. Vanguard Capital Management reported 25,933,824 shares, 6.53%, at March 31, while The Vanguard Group reported zero shares at March 13 in the reorganization of its advisory operations, a transfer rather than a sale. Capital World Investors reported 22,276,996 shares, 5.6%, at June 30. Baillie Gifford reported 18,206,778 shares, 4.59% — below the threshold, which makes its amendment an exit. Schedule 13G/A, FMR, November 5, 2026 13G, Vanguard Capital Management 13G, Capital World Investors 13G/A, Baillie Gifford
Insider filings in the period are exercises and sales, not purchases. Stéphane Bancel’s August 7, 2026 Form 4 reports option exercises at $19.15 and sales of 499,246 shares in four lots; Stephen Hoge filed exercises at $12.21 followed by sales in September, October and November, including 39,160 shares on November 16; Juan Andres was granted 7,898 stock options and 16,955 restricted stock units on November 5 under award code A, which are grants. No Form 4 in the period reports a code P open-market purchase. Form 4, Bancel Form 4, Hoge Form 4, Andres
Short interest was 33,191,285 shares at the October 30 settlement date, about 8.2% of the shares outstanding (Merlintrader calculation) and 1.8 days to cover on average volume of 18.8 million shares. It was 52,809,184 at August 14 and 53,185,640 at June 30; the decline between mid-August and late October is consistent with covering around the melanoma data, though Nasdaq’s figures do not say who covered or why. Eight percent short is a positioning fact with two readings: it can amplify the reaction to good news, and it says many holders expect disappointment. Nasdaq short-interest table, October 30, 2026
12 Government contracts, patents and litigation
The U.S. federal program that built Moderna is over. Its agreement with the Biomedical Advanced Research and Development Authority began in April 2020 with an award of up to $483 million and grew through amendments to a maximum of about $1.8 billion covering late-stage development, a 30,000-participant Phase 3 study, pediatric trials and pharmacovigilance. All options were exercised and the contract concluded on June 15, 2025, with about $62 million of remaining funding the company does not expect to use in material part. No filing describes a current U.S. federal procurement program for mRNA vaccines; U.S. revenue now runs through the commercial channel. Form 10-K, BARDA agreement
The government exposure that remains is contractual and mostly foreign: strategic agreements with the United Kingdom, Canada and Australia combine product sales with stand-ready manufacturing revenue of $94 million in nine months, and a five-year COVID vaccine agreement was signed with a Mexican manufacturer in September 2026. Governments that fund development or buy at scale keep rights commercial customers do not have, from audit and termination to the Bayh-Dole march-in rights that would let a federal agency license patents to a third party on public-health grounds. Form 10-K, government contracts
Patents are the larger exposure. The Arbutus and Genevant settlement of March 3, 2026 resolved all worldwide litigation over Spikevax and mRESVIA and covers the full infectious disease portfolio, with no future royalties. Moderna paid $950 million in July 2026, recorded $876 million in cost of sales in the first quarter and capitalized $74 million as an intangible amortized over about three years. It has appealed the decision on 28 U.S.C. § 1498 to the Federal Circuit and could owe up to $1.3 billion more; no accrual has been recorded because the company does not consider the loss probable. Form 10-Q, Note 12 Form 8-K, March 5, 2026
The offensive case against Pfizer and BioNTech weakened in September 2026, when the Technical Board of Appeal of the European Patent Office revoked European Patent No. 3 590 949 in all contracting states; the Belgian, Irish and Dutch proceedings were dismissed and the German and UK cases await the written decision. Moderna opened a new front the same month in the Hamburg Local Division of the Unified Patent Court on European Patent No. 3 981 437. CureVac has sued in Delaware, The Hague, Barcelona and the Swiss Federal Patent Court, and complaints from Northwestern University, Bayer and Monsanto, mNG Bio, BioNTech in Delaware and four Sanofi subsidiaries are pending. Form 10-Q, Part II, Item 1
Two cases ended. On October 28, 2026 Moderna and GSK agreed to settle all disputes pending in the United States and Europe with cross-licenses in infectious disease and no payments. The shareholder class action over statements about the RSV vaccine, filed in 2024, was dismissed with prejudice on October 13, 2026, subject to appeal and to related derivative complaints. Form 10-Q, legal proceedings
13 Red flags, the next test and the assessment
The first red flag is concentration. COVID vaccines were 98% of product sales in the September quarter and the other approved products contributed $29 million between them, almost all of it mRESVIA. A company with five approvals and one disease paying the bills has not diversified; it has added options. Until mFLUSIVA has a full contracting season, revenue will follow the COVID season and the government delivery calendar.
The second is the shape of the year. The guidance implies fourth-quarter revenue of $389–583 million against $678 million a year earlier, and the third quarter held 71% of nine-month revenue: a business whose profit is produced in one quarter, and whose guidance implies a decline in the next, depends on a single season with no buffer. The third is the legal tail: $1.3 billion contingent on one appeal, a revoked European patent and new CureVac actions in three jurisdictions.
The fourth is governance turnover. Juan Andres returned as Chief Operating Officer on October 5, 2026, a new role that absorbs the manufacturing organization after Jerh Collins retired as Chief Technical Operations and Quality Officer, and Shannon Thyme Klinger, Chief Legal Officer, leaves by March 31, 2027 under a retirement agreement signed on November 13, 2026, with $1,628,300 of severance and additional payments of $2.5 million and up to $5.5 million contingent on the Arbutus and Pfizer litigations. Two senior roles changed hands in the year of the Phase 3 readout, a fact to weigh rather than a verdict.
The fifth is what the market is being asked to believe. A positive Phase 3 in adjuvant melanoma with a 42% reduction in the risk of recurrence or death supports a franchise; it is not a launch, a price, a label or a reimbursement decision. The next tests are concrete: a filing for intismeran, a fourth quarter inside the guided range, and pivotal propionic acidemia data by December 31, 2026. If those arrive in order, Moderna enters 2027 as a two-franchise company with $8 billion of liquidity. If the fourth quarter lands at the bottom of the range and the filing slips, the profitable quarter becomes a seasonal artifact and the $3.0 billion of converts the largest fixed claim in the capital structure.
Merlintrader Health Score · $MRNA
3.65out of 5
Reassessed on November 19, 2026, after the September 30, 2026 Form 10-Q, the November 6 results release and the November 9 credit amendment. Calculation: 4.0×30% + 4.0×30% + 2.5×20% + 4.0×10% + 3.5×10% = 1.20 + 1.20 + 0.50 + 0.40 + 0.35 = 3.65. The score describes financial and operational robustness over twelve to eighteen months; it is not a rating, a target price or an indication to buy or sell.
Red flags
- COVID vaccines produced $1,244 million of $1,273 million of product sales in the September quarter; the other three products contributed $29 million.
- Full-year guidance implies fourth-quarter revenue of $389–583 million against $678 million in the fourth quarter of 2025.
- The norovirus Phase 3 interim did not meet its early-success criteria.
- Up to $1.3 billion may be payable on the Arbutus and Genevant appeal, with no accrual recorded because the loss is not considered probable.
- The European Patent Office revoked European Patent No. 3 590 949 in September 2026, removing the basis of the Belgian, Irish and Dutch proceedings.
MRNA Stock FAQ: Moderna Questions Answered
When is the next Moderna stock catalyst?
December 12, 2026, when an abstract on mRNA-2808 is presented orally at the American Society of Hematology meeting, and by December 31, 2026, the end of the window in which Moderna expects pivotal data from the propionic acidemia study of mRNA-3927. The intismeran filing has no announced date. Details.
How much revenue does Moderna make?
Moderna reported $1,313 million of revenue in the quarter ended September 30, 2026, of which $1,273 million was product sales, and $1,847 million in nine months. Full-year 2025 revenue was $1,944 million; 2026 guidance is 15%–25% growth. Details.
How much cash does Moderna have?
$7,976 million of cash, cash equivalents and investments at September 30, 2026, against $3,549 million of debt: $2,958 million of convertible notes and a $591 million term loan. The company guides year-end cash to $8.1–8.3 billion and says its resources fund at least twelve months. Details.
What did the melanoma trial show?
In INTerpath-001, intismeran autogene plus KEYTRUDA reduced the risk of recurrence or death by 42% (hazard ratio 0.58; p<0.001) and the risk of distant metastasis or death by 38% (0.62; p=0.002) against KEYTRUDA alone after a median follow-up of 24.6 months, as presented at ESMO. Overall survival data are not mature. Details.
What legal cases does Moderna still face?
The Arbutus and Genevant case settled in March 2026 for $950 million, with an appeal pending that could require up to $1.3 billion more; patent actions with Pfizer and BioNTech continue in Germany, the UK and the Unified Patent Court; CureVac has cases in Delaware, The Hague, Barcelona and Switzerland; and complaints from Northwestern University, Bayer and Monsanto, mNG Bio, BioNTech and four Sanofi subsidiaries are pending. Details.
Is Moderna stock at risk of dilution?
Yes. There were 404,620,975 shares at October 30, 2026, 27.18 million options and 11.20 million unvested units at December 31, 2025, 38 million shares reserved for awards already granted, and up to about 21 million shares under the 2032 notes, partly offset by capped calls on about 14 million shares. Details.
Primary sources
- Third-quarter 2026 results and 2026 financial framework, November 6, 2026 (Form 8-K, Exhibit 99.1)
- Form 10-Q for the quarter ended September 30, 2026
- Form 8-K, retirement of the Chief Legal Officer, November 13, 2026
- Form 8-K, Amendment No. 1 to the Ares credit agreement, November 16, 2026
- Form 8-K, Arbutus settlement, March 5, 2026 · FDA refusal-to-file letter
- Second-quarter 2026 results, July 31, 2026 · first quarter, May 1, 2026
- Full-year 2025 results, February 13, 2026
- Form 10-K for 2025
- 13G/A, FMR LLC · 13G, Vanguard Capital Management · 13G, Capital World Investors · 13G/A, Baillie Gifford
- Form 4, Stéphane Bancel · Form 4, Stephen Hoge · Form 4, Juan Andres
- Nasdaq short interest, October 30, 2026
- Hald Albertsen et al., Advanced Drug Delivery Reviews 2022, lipid components in lipid nanoparticles
- Wilson et al., New England Journal of Medicine 2023, mRNA-based RSV vaccine · Papi et al., NEJM 2023, RSVPreF3 OA · Walsh et al., NEJM 2023, bivalent RSVpreF · Ison et al., The Lancet Respiratory Medicine 2025
- Weber et al., The Lancet 2024, KEYNOTE-942 · Carlino et al., JCO Oncology Advances 2026 · Khattak et al., Journal of Clinical Oncology 2026
- Wu et al., The Lancet Respiratory Medicine 2023, vaccine effectiveness · Gram et al., PLOS Medicine 2022 · Chemaitelly et al., Nature Communications 2022 · Alhumaid et al., BMC Infectious Diseases 2026
- Fierro et al., Frontiers in Immunology 2025, reactogenicity across four mRNA vaccines · Oster et al., JAMA 2022
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here recommends buying, selling or holding $MRNA or any other security.
Figures are taken from U.S. Securities and Exchange Commission filings, company press releases, peer-reviewed literature and market-data providers, with their reference dates. Data can change without notice; readers should verify every figure against the primary source.
Biotechnology companies carry high clinical, regulatory and commercial risk: trials fail, approvals are delayed or restricted, payers refuse coverage, patents are litigated and companies that spend ahead of revenue raise capital on whatever terms the market offers. This company reported five approved products but 98% of product sales from COVID vaccines in the September 2026 quarter, carries $3.5 billion of debt after issuing $3.0 billion of convertible notes, and faces patent litigation in the United States and Europe with up to $1.3 billion contingent on one appeal. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



